Aug 14, 2024 / 12:30PM GMT
Operator
Good morning, and welcome to the Verrica Pharmaceuticals second quarter 2024 earnings conference call. After the speaker's remarks, there will be a question-and-answer session. (Operator Instructions) Please note today's call will be recorded. (Operator Instructions) It is now my pleasure to turn the call over to today's host, Kevin Gardner, Managing Director with LifeSci Partners. Please go ahead.
Kevin Gardner - LifeSci Partners - Managing Director
Thank you, operator. Hello, everyone, and welcome to Verrica Pharmaceuticals second quarter 2024 corporate update and earnings conference call. With me on the line this morning are Ted White, President and Chief Executive Officer of Verrica; Joe Bonaccorso, Chief Commercial Officer; Terry Kohler, Chief Financial Officer; Dr. Gary Goldenberg, Verrica's Chief Medical Officer; and Chris Hayes, Verrica's Chief Legal Officer.
As a reminder, during today's call, management will make forward-looking statements. These statements may include expectations related to the commercialization of YCANTH, VP-102 for the
Q2 2024 Verrica Pharmaceuticals Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot